Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association (NYBA) "The Cures Start Here" Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.
“Acorda exemplifies the vibrancy of the New York biotechnology industry and NYBA is pleased to recognize Dr. Cohen for his dedication to helping people with neurological disease, and for his ongoing commitment to the growth of the biotechnology industry in New York.”
"Under Dr. Cohen's leadership, Acorda recently received FDA approval for AMPYRA™, which represents a significant contribution to the treatment of people with multiple sclerosis," said Nathan Tinker, Ph.D., Executive Director of NYBA. "Acorda exemplifies the vibrancy of the New York biotechnology industry and NYBA is pleased to recognize Dr. Cohen for his dedication to helping people with neurological disease, and for his ongoing commitment to the growth of the biotechnology industry in New York."
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke